Steven Cohen’s Cyclerion Therapeutics CYCN Stock Holding History

Steven Cohen’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-6,961	Closed	-$379K	–	831
2019 Q4	$379K	Buy	+6,961	New	+$650K	﹤0.01%	797

Other funds holding CYCN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Steven Cohen's CYCN Position: Q1 2020 in Review

Steven Cohen sold out of Cyclerion Therapeutics (CYCN) in Q1 2020, closing a stake of 6,961 shares — an estimated $379K sold.

Steven Cohen first reported a position in CYCN in Q4 2019 and held it in 1 quarter. The position peaked at $379K in Q4 2019. 80 funds tracked by Wall St. Rank hold CYCN as of Q1 2020.

Steven Cohen reported no remaining Cyclerion Therapeutics position as of Q1 2020 after selling out during the quarter.
Steven Cohen sold 6,961 Cyclerion Therapeutics shares in Q1 2020, an estimated $379K.
Steven Cohen first reported a position in Cyclerion Therapeutics in Q4 2019 and held it in 1 quarter.
Steven Cohen's Cyclerion Therapeutics position peaked at $379K in Q4 2019.
80 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2020.

Based on Point72 Asset Management's 13F filing for Q1 2020, filed 15 May 2020.